ATE323151T1 - Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen - Google Patents

Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen

Info

Publication number
ATE323151T1
ATE323151T1 AT02750989T AT02750989T ATE323151T1 AT E323151 T1 ATE323151 T1 AT E323151T1 AT 02750989 T AT02750989 T AT 02750989T AT 02750989 T AT02750989 T AT 02750989T AT E323151 T1 ATE323151 T1 AT E323151T1
Authority
AT
Austria
Prior art keywords
cells
applications
vivo isolated
clones
immunosupressive activity
Prior art date
Application number
AT02750989T
Other languages
English (en)
Inventor
Maria Grazia Roncarolo
Megan Levings
Original Assignee
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23131593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE323151(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fond Telethon filed Critical Fond Telethon
Application granted granted Critical
Publication of ATE323151T1 publication Critical patent/ATE323151T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02750989T 2001-05-30 2002-05-29 Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen ATE323151T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29403001P 2001-05-30 2001-05-30

Publications (1)

Publication Number Publication Date
ATE323151T1 true ATE323151T1 (de) 2006-04-15

Family

ID=23131593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02750989T ATE323151T1 (de) 2001-05-30 2002-05-29 Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen

Country Status (6)

Country Link
US (2) US20040173778A1 (de)
EP (1) EP1409650B1 (de)
JP (1) JP2004527263A (de)
AT (1) ATE323151T1 (de)
DE (1) DE60210623T2 (de)
WO (1) WO2002097070A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0302167D0 (en) * 2003-01-30 2003-03-05 Leuven K U Res & Dev T cell phenotype
US7651855B2 (en) * 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
US20060188485A1 (en) * 2003-07-11 2006-08-24 Bernd Karl Friedrich Kremer Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity
WO2005118788A2 (en) * 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1851308B1 (de) * 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Gegen ein spezifisches antigen aktivierte cd4+ cd25+ t-zellen
EP1712615A1 (de) * 2005-04-15 2006-10-18 Txcell In vitro Herstellung einer Zellpopulation mittels Nährzellen
JP2008029440A (ja) * 2006-07-27 2008-02-14 Asahi Kasei Kuraray Medical Co Ltd 白血球除去治療の効果の予測方法及びキット
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
JP5543207B2 (ja) * 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
ES2637812T3 (es) 2008-02-14 2017-10-17 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
EP2252329B1 (de) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Beseitigung von immunreaktionen gegen virale vektoren
EP2626081B1 (de) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogene Beeinflussung von Tumoren und Tumorzellen
WO2010135255A1 (en) * 2009-05-18 2010-11-25 Therakos, Inc. Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
DE11787873T1 (de) 2010-11-25 2013-12-12 Imnate Sarl Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US9938498B2 (en) * 2012-05-07 2018-04-10 Nkmax Co., Ltd. Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
WO2014097995A1 (ja) * 2012-12-20 2014-06-26 三菱電機株式会社 導光体、光源装置及び画像読取装置
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
BR112018071466A2 (pt) 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
WO2018106885A1 (en) 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
EP4034639A1 (de) 2019-09-26 2022-08-03 Cellenkos, Inc. Zusammensetzungen, die regulatorische t-zellen umfassen, und verfahren zum herstellen und verwenden derselben
WO2022005462A1 (en) * 2020-06-30 2022-01-06 Tr1X, Inc. Poly-donor cd4+ t cells expressing il-10 and uses thereof

Also Published As

Publication number Publication date
WO2002097070A1 (en) 2002-12-05
US20090010950A1 (en) 2009-01-08
DE60210623T2 (de) 2007-02-15
EP1409650B1 (de) 2006-04-12
DE60210623D1 (de) 2006-05-24
EP1409650A1 (de) 2004-04-21
US20040173778A1 (en) 2004-09-09
JP2004527263A (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
ATE323151T1 (de) Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen
IL273422A (en) Methods and systems for extracorporeal organ treatment
WO2003000038A3 (en) Compositions and methods for modulating plant development
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
SG163588A1 (en) Methods for identifying agents and conditions that modulate neurogenesis
WO2017066561A3 (en) Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
ATE305448T1 (de) Phenylalaninderivate als herbizide
EP1551953A4 (de) Modulation von stamm- und vorläuferzelldifferenzierung,versuchsmuster und entsprechende anwendungen
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
NO20091976L (no) Nye forbindelser
MX2010001657A (es) Reguladores de mmp-9 y usos de los mismos.
WO2004015077A3 (en) Compositions and methods for neural differentiation of embryonic stem cells
EP4491635A3 (de) Anti-ccr8 antikörper
ATE357469T1 (de) Sterilisierende polymere und deren herstellung und verwendung
SE0302129D0 (sv) Farmaceutiska kompositioner med antibiotisk aktivitet
JOP20220206A1 (ar) الخلايا التائية واستخداماتها
IL187489A0 (en) Novel substrate for rpn 11 enzymatic activity
ATE403712T1 (de) Verwendung von polymerisaten, enthaltend thermoplastische polymere als filterhilfs- und/oder stabilisierungsmittel
ATE404602T1 (de) Wässrige polyurethanzubereitungen
ATE363890T1 (de) Kationische polymerisate und deren verwendung in kosmetischen formulierungen
WO2023158750A3 (en) Systems for cell programming and methods thereof
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)
DE60210970D1 (de) Mutante formen von etxb und ctxb und ihre verwendung als träger
CA3156248A1 (en) ANTI-CD37-MAYTANSINE ANTIBODY CONJUGATES AND METHODS OF USE THEREOF
MX2024003331A (es) Moleculas de union a d3 y usos de estas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties